pharmacological intervention to modulate hdl: what do we target?
Clicks: 194
ID: 257792
2018
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
30.0
/100
194 views
40 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #303 of 333 articles by views in chemical research in chinese universities
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 333 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
The cholesterol concentrations of low-density lipoprotein (LDL) and high-density lipoprotein (HDL) have traditionally served as risk factors for cardiovascular disease. As such, novel therapeutic interventions aiming to raise HDL cholesterol have been tested in the clinical setting. However, most trials led to a significant increase in HDL cholesterol with no improvement in cardiovascular events. The complexity of the HDL particle, which exerts multiple physiological functions and is comprised of a number of subclasses, has raised the question as to whether there should be more focus on HDL subclass and function rather than cholesterol quantity. We review current data regarding HDL subclasses and subclass-specific functionality and highlight how current lipid modifying drugs such as statins, cholesteryl ester transfer protein inhibitors, fibrates and niacin often increase cholesterol concentrations of specific HDL subclasses. In addition this review sets out arguments suggesting that the HDL3 subclass may provide better protective effects than HDL2.
| Reference Key |
woudberg2018frontierspharmacological
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Nicholas J. Woudberg;Sarah Pedretti;Sarah Pedretti;Sandrine Lecour;Rainer Schulz;Nicolas Vuilleumier;Richard W. James;Miguel A. Frias;Miguel A. Frias |
| Journal | chemical research in chinese universities |
| Year | 2018 |
| DOI |
10.3389/fphar.2017.00989
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.